EP1504121A4 - Device and method for high-throughput quantification of mrna from whole blood - Google Patents
Device and method for high-throughput quantification of mrna from whole bloodInfo
- Publication number
- EP1504121A4 EP1504121A4 EP03724238A EP03724238A EP1504121A4 EP 1504121 A4 EP1504121 A4 EP 1504121A4 EP 03724238 A EP03724238 A EP 03724238A EP 03724238 A EP03724238 A EP 03724238A EP 1504121 A4 EP1504121 A4 EP 1504121A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mrna
- quantification
- quantified
- leukocytes
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to high-throughput isolation and quantification of mRNA from whole blood. More particularly, this invention relates to a method and device for isolating and amplifying mRNA using combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
- RNA ribonucleic acid
- This information may be of use in clinical practice, to diagnose infections, to detect the presence of cells expressing oncogenes, to detect familial disorders, to monitor the state of host defense mechanisms and to determine the HLA type or other marker of identity.
- RNA exists in three functionally different forms: ribosomal RNA (rRNA), transfer RNA (tRNA) and messenger RNA (mRNA). Whereas stable rRNA and tRNA are involved in catalytic processes in translation, mRNA molecules carry genetic information.
- RNA Only about 1-5% of the total RNA consists of mRNA, about 15% of tRNA and about 80% of rRNA.
- mRNA is an important diagnostic tool, particularly when it is used to quantitatively observe up- or down-regulation of genes.
- Human peripheral blood is an excellent clinical resource for mRNA analysis.
- the detection of specific chimeric mRNA in blood indicates the presence of abnormal cells and is used in molecular diagnostics for chronic myelogenous leukemia (CML) (Kawasaki E.S., Clark S.S., Coyne M.Y., Smith S.D., Champlin R., Witte O.N., and McCormick F.P. 1988.
- CML chronic myelogenous leukemia
- Micrometastatic cancer cells can also be detected in blood by measuring cancer-specific mRNA, such as carcinoembryonic antigen (CEA) for colon cancer, prostate specific antigen (PSA) for prostate cancer, thyroglobulin for thyroid cancer (Wingo S.T., Ringel M.D., Anderson J.S., Patel A.D., Lukes Y.D., Djuh Y.Y., Solomon B., Nicholson D., Balducci- Silano P ., Levine M.A., Francis G.L., and Tuttle R.M. 1999. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. Clin. Chem.
- mRNA quantities may change during lengthy isolation processes. While no method exists for the isolation of cancer cells from blood, gene amplification technologies enable the identification and quantification of specific mRNA levels even from a pool of different genes, making whole blood an ideal material for mRNA analysis when gene-specific primers and probes are available.
- RNA extraction methods are available for whole blood applications (de Vries T.J., Fourkour A., Punt C.J., Ruiter D.J., and van Muijen G.N. 2000. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
- the present invention discloses an efficient high throughput method and device for isolating and quantifying mRNA directly from whole blood, with reproducible recovery, using combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
- One aspect of the invention includes a method of high throughput quantification of mRNA in whole blood, including the steps of: (a) collecting whole blood; (b) removing erythrocytes and blood components from the whole blood by filtration to yield leukocytes on a filter membrane; (c) subjecting the leukocytes to cell lysis to produce a lysate containing mRNA; (d) transferring the lysate to an oligo(dT)-immobilized plate to capture the mRNA; and (e) quantifying the mRNA.
- an anticoagulant is administered to the whole blood prior to collection of leukocytes.
- filter membranes can be layered together to increase the yield of captured leukocytes.
- the leukocytes that are trapped on the filter membrane are lysed using a lysis buffer to release mRNA from the leukocytes.
- the transfer of lysate to the oligo(dT)-immobilized plate can be accomplished using centrifugation, vacuum aspiration, positive pressure, or washing with ethanol followed by vacuum aspiration.
- the mRNA is quantified by producing cDNA and amplifying the cDNA by PCR.
- Another aspect of the invention includes a device for performing high throughput quantification of mRNA in whole blood, wherein the device includes: (a) a multi-well plate containing: a plurality of sample-delivery wells; a leukocyte-capturing filter underneath the wells; and an mRNA capture zone underneath the filter which contains immobilized oligo(dT); and (b) a vacuum box adapted to receive the filter plate to create a seal between the plate and the box.
- the leukocytes are captured on a plurality of filter membranes that are layered together.
- the vacuum box is adapted to receive a source of vacuum.
- a multi-well supporter is inserted between the vacuum box and the multi-well plates.
- kits which contains: the device for performing high throughput quantification of mRNA in whole blood, heparin, a hypotonic buffer, and a lysis buffer.
- Another aspect of the invention includes a fully automated system for performing high throughput quantification of mRNA in whole blood, including: a robot to apply blood samples, hypotonic buffer, and lysis buffer to the device; an automated vacuum aspirator and centrifuge, and automated PCR machinery.
- FIG. 1 is an exploded drawing of the high throughput mRNA device.
- FIG. 2 depicts the multi-well plate, including the leukocyte filter and oligo-(dT)- immobilized filter wells, of the high throughput mRNA device.
- FIG. 3 is a graph showing the efficiency of leukocyte trapping of fresh and frozen blood samples on filter plates.
- FIG. 4 is a graph showing the effect of number of washes of blood on mRNA quantification.
- FIG. 5 is a graph showing the effect of final treatments of filter plates before cell lysis on mRNA quantification.
- FIG. 6 is a graph showing how lysis buffer inhibits RNase.
- FIG. 7 is a graph showing optimal concentrations of reverse transcriptase for mRNA quantification.
- FIG. 8 is a graph showing optimal values of cDNA for PCR to capture mRNA.
- FIG. 9 is a graph showing the hybridization kinetics of the invention.
- FIG. 10 is a graph showing the linear relationship between whole blood volume used per well and mRNA quantification.
- the present invention allows analysis of larger volumes of unprepared whole blood, provides an efficient means of analyzing mRNA that is derived exclusively from white blood cells; removes rRNA and tRNA, provides consistent mRNA recovery, and is easily adaptable to automation.
- the present invention provides a sensitive quantification system, including: absolute quantification using real time PCR, and excellent reproducibility with coefficients of variation ranging from 20-25%.
- the present invention is applicable to various disease targets (Table I). Table I. Clinical targets
- FIGs 1 and 2 show a preferred structure for implementing the high throughput mRNA quantification of the present invention.
- a vacuum box 10 forms the base of the structure.
- the vacuum box can be made of any material sufficiently strong to withstand vacuum aspiration; however, disposable plastic material is preferred.
- the vacuum box is adapted to receive a source of vacuum in order to perform vacuum aspiration 12.
- a filter plug 14 is located within the vacuum aspirator adapter of the vacuum box.
- the vacuum box 10 preferably has a ledge 16 to mate with a multi-well filter plate 40, or optionally, a multi- well supporter 20.
- the multi-well supporter 20 is optionally provided inside the upper part of the vacuum box so as to support the multi-well filterplate 40.
- One preferred embodiment involves a simple, reproducible, and high throughput method of mRNA quantification from whole blood. The rapid protocol minimizes the secondary induction or degradation of mRNA after blood draw, and the use of 96-well filterplates and microplates allows the simultaneous manipulation of 96 samples. Minimal manipulation during the procedure provides for very small sample-to-sample variation, with coefficient of variation (CV) values of less than 30%, even when PCR is used as a means of quantification.
- CV coefficient of variation
- the method involves preparation of the vacuum box.
- a blood encapsulator such as polyacrylate polymer matrix (Red Z, Safetec) is added to the vacuum box to solidify the blood.
- a multi-well supporter is then placed in the vacuum box.
- a sealing gasket made of silicon-based rubber or other soft plastics is then placed on top of the multi-well plate supporter.
- a filter plug (X-6953, 60 ⁇ Filter Plug HDPE, Porex Products Groups) is placed in the vacuum aspirator adapter of the vacuum box.
- the method involves the preparation of the filter plate. Either glassfiber membranes or leukocyte filter membranes can be used to capture leukocytes.
- multiple-well filterplates are constructed using glassfiber membranes or leukocyte filter membranes to enable the simultaneous processing of multiple blood specimens.
- filters for capturing leukocytes are disclosed in U.S. patent numbers 4,925,572 and 4,880,548, the disclosures of which are hereby incorporated by reference.
- Adsorption of leukocytes on fiber surfaces is generally accepted as the mechanism of leukocyte removal. Since the surface area of a given weight of fibers is inversely proportional to the diameter of the fibers, it is to be expected that finer fibers will have higher capacity and that the quantity as measured by weight of fibers necessary to achieve a desired efficiently will be less if the fibers used are smaller in diameter.
- PBT has been the principal resin used for the development of the products of this invention and is the resin used in the examples. It should be noted, however, that other resins may be found which can be fiberized and collected as mats or webs with fibers as small as 1.5 micrometers or less, and that such products, with their critical wetting surface tensions adjusted as necessary to the optimum range, may be well suited to the fabrication of equally efficient but still smaller leukocyte depletion devices. Similarly, glass fibers, appropriately treated, may be usable to make effective devices.
- the filter plate is placed in the vacuum box.
- multiple filter membranes are layered together to increase the amount of leukocytes captured from whole blood.
- the filter plate is placed upon the plate supporter and the sealing gasket.
- the filter plate is sealed with a plastic adhesive tape (Bio-Rad 223-9444), and the tape is cut to allow access to a desired number of wells.
- each well to which a sample will be added is washed with a hypotonic buffer (200 ⁇ L 5mM Tris, pH 7.4).
- the method preferably involves collecting blood, adding the blood to the multi-well filter plate, and removal of erythrocytes and other non-leukocyte components.
- whole blood can be drawn into blood collection tubes containing anticoagulants, which increase the efficiency of the leukocyte filtering.
- the anticoagulant, heparin is particularly effective in increasing the efficiency of leukocyte filtering.
- the blood sample can be frozen, which removes some of the RNases that destroy mRNA.
- the wells can be washed with a hypotonic buffer. Once blood has been added to the desired number of wells on the filterplate, the blood is filtered through the filter membrane. Filtration can be affected through any technique known to those of skill in the art, such as centrifugation, vacuum aspiration, or positive pressure.
- vacuum aspiration is commenced (with 6 cm Hg) after the blood samples have been added to the filterplate wells.
- Each well is washed several times with a hypotonic buffer (12x with 200 ⁇ L 5mM Tris, pH 7.4).
- each well containing a sample is washed with ethanol (lx with 200 ⁇ L 100% ethanol), which dries the filter membrane and significantly increases the efficiency of leukocyte trapping during vacuum aspiration.
- the vacuum is then applied (20 cmHg for >2 min).
- the method involves cell lysis and hybridization of mRNA to the oligo(dT)- immobilized within the mRNA capture zone.
- Lysis buffer is applied to the filterplate wells (40 ⁇ L/well), and incubation is allowed to occur (room temperature for 20 min) to release mRNA from the trapped leukocytes.
- the multi-well filterplate is sealed in a plastic bag and centrifuged (IEC MultiRF, 2000 rpm, at 4 C, for 1 min). Lysis buffer is then added again (20 ⁇ L/well), followed by centrifugation (IEC MultiRF, 3000 rpm, at 4 C, for 5 min). The multi-well filterplate is then removed from the centrifuge and incubated (room temperature for 2hrs).
- the method involves quantification of mRNA, which in a preferred embodiment entails cDNA synthesis from mRNA and amplification of cDNA using PCR.
- the multi-well filterplate is washed with lysis buffer (150 ⁇ L/well x 3 times, manual) and wash buffer (150 ⁇ L/well x 3 times, manual or BioTek #G4).
- a cDNA synthesis buffer is then added to the multi-well filterplate (40 ⁇ L/well, manual or I&J #6).
- Axymat Amgen AM-96-PCR-RD
- the multi- well filterplate can then be centrifuged (2000 rpm, at 4 C for 1 min).
- PCR primers are added to a 384 well PCR plate, and the cDNA is transferred from the multi-well filterplate to the 384 well PCR plate.
- the PCR plate is centrifuged (2000 rpm, at 4 C for 1 min), and real time PCR is commenced (TaqMan/SYBER).
- the device includes a multi-well filterplate containing: multiple sample-delivery wells, a leukocyte-capturing filter underneath the sample-delivery wells, and an mRNA capture zone under the filter, which contains oligo(dT)-immobilized in the wells of the mRNA capture zone.
- a multi-well filterplate containing: multiple sample-delivery wells, a leukocyte-capturing filter underneath the sample-delivery wells, and an mRNA capture zone under the filter, which contains oligo(dT)-immobilized in the wells of the mRNA capture zone.
- several filtration membranes can be layered together.
- the multi-well plate is fitted upon a vacuum box, which is adapted to receive the plate and to create a seal between the multi-well plate and the vacuum box.
- the vacuum box is adapted to receive a source of vacuum in order to perform vacuum aspiration.
- a multi- well supporter is placed in the vacuum box, below the multi-well filterplate.
- a sealing gasket which can be made from soft plastic such as silicon-based rubber, is inserted between the multi-well supporter and the multi- well filterplate.
- kits for high-throughput quantification of mRNA from whole blood includes: the device for high-throughput quantification of mRNA from whole blood; heparin-containing blood-collection tubes; a hypotonic buffer; and a lysis buffer.
- Another preferred embodiment involves a fully automated system for performing high throughput quantification of mRNA in whole blood, including: robots to apply blood samples, hypotonic buffer, and lysis buffer to the device; an automated vacuum aspirator and centrifuge, and automated PCR machinery.
- Example Various protocols of the method of the present invention were tested and used to quantify ⁇ -actin mRNA and CD4 mRNA from whole blood.
- ACD Three anticoagulants were tested: ACD, EDTA, and heparin, with heparin resulting in the highest percent of leukocyte retention.
- Leukosorb membranes While Leukosorb membranes have been used for ACD blood in transfusion, approximately 15-40% of leukocytes passed through even when four layers of membranes were simultaneously used.
- EDTA blood was tested; the capacity and leukocyte retention was found to be similar to those for ACD. Most notably, however, was that 100% of the leukocytes in heparin blood were trapped on the Leukosorb membranes. The capture of 100% of leukocytes from heparin blood shows the reliability of quantification of mRNA using the present invention.
- glassfiber membranes accepted only 40 ⁇ L of whole blood, even when membranes were washed with hypotonic buffer (50 mM Tris, pH 7.4) to burst erythrocytes.
- hypotonic buffer 50 mM Tris, pH 7.4
- Leukosorb filters accepted significantly larger amounts of whole blood than the glassfiber filters, as indicated in Table II.
- (A, H) represents anticoagulants used in the experiments.
- FIG 5 indicates that while vacuum aspiration resulted in better CD4 mRNA quantification than centrifugation, washing blood samples with ethanol prior to vacuum aspiration yields the most mRNA.
- amplification primers are N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe-N-(tyl)-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- FIG 6 indicates that lysis buffer plays an important role in RNase inhibition; eosinophils are filled with RNases, which are inactivated by the lysis buffer.
- the multi-well filterplate was then sealed in a plastic bag and centrifuged (IEC MultiRF, 2000 rpm, at 4 C, for 1 min). Lysis buffer was then added again (20 ⁇ L/well), followed by centrifugation (IEC MultiRF, 3000 rpm, at 4 C, for 5 min). The multi-well filterplate was then removed from the centrifuge and incubated at room temperature for two hours to allow hybridization of poly(A)+ RNA tails with the immobilized oligo(dT).
- the multi-well filterplates were then washed three times with 150 ⁇ L Lysis Buffer to remove remaining ribonucleases, followed by three washes with 150 ⁇ L Wash Buffer (BioTek #G4) to remove the Lysis Buffer, which contained some inhibitors of cDNA synthesis.
- the Wash Buffer was completely removed from the multi-well filterplates, and cDNA was synthesized in each well by adding 40 ⁇ L of premixed cDNA buffer.
- the cDNA buffer consists of: 5x First Strand Buffer (Promega M531A, 10 mM dNTP (Promega stock, 20x)), Primer (5 ⁇ M, #24), RNasin (Promega N211A, 40 U/ ⁇ L), M-MLV reverse transcriptase (Promega M170A, 200 U/ ⁇ L), and DEPC water.
- FIG 7 indicates that the optimal concentration of MMLV for mRNA quantification is 0.25 units/well.
- Axymat (Amgen AM-96-PCR-RD) was placed on the multi-well filterplate, which was then placed on a heat block (37 C, VWR) and incubated (>90 min). The multi-well filterplate was then centrifuged (2000 rpm, at 4 C for 1 min). PCR primers were added to a 384-well PCR plate, and the cDNA was transferred from the multi-well filterplate to the 384-well PCR plate.
- FIG 8 indicates that the optimal value of cDNA for PCR is approximately 2 ⁇ L/well. The PCR plate was centrifuged (2000 rpm, at 4 C for 1 min), and real time PCR was commenced (TaqMan/SYBER).
- the method of the current invention has high mRNA specificity; amplification of CD4 mRNA with TaqMan qPCR resulted in undetectable DNA contamination ( ⁇ 10 copies/well).
- the present invention results in low coefficients of variation for mRNA quantification.
- Hybridization for two hours resulted in a coefficient of variation of less than 13%, as compared to traditional coefficients of variation of approximately 300% for mRNA quantification.
- the linear results show that the amount of mRNA that is captured is directly proportional to the volume of whole blood used per well, making the present invention a reliable and reproducible method of quantifying mRNA.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
Description
DEVICE AND METHOD FOR HIGH-THROUGHPUT QUANTIFICATION OF
MRNA FROM WHOLE BLOOD
Background of the Invention Field of the invention The present invention relates to high-throughput isolation and quantification of mRNA from whole blood. More particularly, this invention relates to a method and device for isolating and amplifying mRNA using combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
Description of the Related Art
Research in the field of molecular biology has revealed that the genetic origin and functional activity of a cell can be deduced from the study of its ribonucleic acid (RNA). This information may be of use in clinical practice, to diagnose infections, to detect the presence of cells expressing oncogenes, to detect familial disorders, to monitor the state of host defense mechanisms and to determine the HLA type or other marker of identity. RNA exists in three functionally different forms: ribosomal RNA (rRNA), transfer RNA (tRNA) and messenger RNA (mRNA). Whereas stable rRNA and tRNA are involved in catalytic processes in translation, mRNA molecules carry genetic information. Only about 1-5% of the total RNA consists of mRNA, about 15% of tRNA and about 80% of rRNA. mRNA is an important diagnostic tool, particularly when it is used to quantitatively observe up- or down-regulation of genes. Human peripheral blood is an excellent clinical resource for mRNA analysis. The detection of specific chimeric mRNA in blood, for example, indicates the presence of abnormal cells and is used in molecular diagnostics for chronic myelogenous leukemia (CML) (Kawasaki E.S., Clark S.S., Coyne M.Y., Smith S.D., Champlin R., Witte O.N., and McCormick F.P. 1988. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl. Acad. Sci. USA 85:5698-5702, Pachmann K., Zhao S., Schenk T., Kantarjian H., El-Naggar A.K., Siciliano M.J., Guo J.Q., Arlinghaus R.B., and Andreeff M. 2001. Expression of bcr-able mRNA individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br. J. Haematol. 112:749-59). Micrometastatic cancer cells can also be detected in blood by measuring cancer-specific mRNA, such as carcinoembryonic antigen (CEA) for colon cancer, prostate specific antigen
(PSA) for prostate cancer, thyroglobulin for thyroid cancer (Wingo S.T., Ringel M.D., Anderson J.S., Patel A.D., Lukes Y.D., Djuh Y.Y., Solomon B., Nicholson D., Balducci- Silano P ., Levine M.A., Francis G.L., and Tuttle R.M. 1999. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. Clin. Chem. 45:785-89), and tyrosinase for melanoma (Pelkey TJ., Frierson H.F. Jr., and Brans D.E. 1996. Molecular and immunological detection of circulating tumor cells and micrometastasis from solid tumors. Clin. Chem. 42:1369-81). Moreover, as the levels of these cancer-specific mRNA can change following treatment, quantification of specific mRNA provides for a useful indicator during treatment follow-up. As blood contains large quantities of non-nucleated erythrocytes (approximately
5 million cells/μL) compared to leukocytes (approximately 5000 leukocytes/μL), the isolation of granulocytes or lymphocytes from whole blood is commonly performed as the first step in mRNA analysis. However, due to inconsistencies in the recovery of specific subsets of leukocytes among different samples, the number of isolated leukocytes is determined for each sample and results are expressed as the quantity of mRNA per leukocytes, not niRNA/μL blood. Moreover, mRNA quantities may change during lengthy isolation processes. While no method exists for the isolation of cancer cells from blood, gene amplification technologies enable the identification and quantification of specific mRNA levels even from a pool of different genes, making whole blood an ideal material for mRNA analysis when gene-specific primers and probes are available.
It is very difficult to isolate pure mRNA from whole blood because whole blood contains large amounts of RNases (from granulocytes) and non-nucleated erythrocytes. Although various RNA extraction methods are available for whole blood applications (de Vries T.J., Fourkour A., Punt C.J., Ruiter D.J., and van Muijen G.N. 2000. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method. Melanoma Research 10:119-26, Johansson M., Pisa E.K., Tormanen V., Arstrand K., and Kagedal Bl. 2000. Quantitative analysis of tyrosinase transcripts in blood. Clin. Chem. 46:921-27, Wingo S.T., Ringel M.D., Anderson J.S., Patel A.D., Lukes Y.D., Djuh Y.Y., Solomon B., Nicholson D., Balducci-Silano P ., Levine M.A., Francis G.L., and Tuttle R.M. 1999. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA
in peripheral blood of healthy subjects. Clin. Chem. 45:785-89), the assay procedures are labor-intensive, require several rounds of centrifugation, and involve careful handling that is essential in eliminating ribonuclease activities.
Consequently, there exists a need for a quick and easy method and device for isolating and quantifying large quantities of mRNA from whole blood. Specifically, there exists a need for a high throughput, whole blood-derived mRNA-processing technology with reproducible recovery and a seamless process to gene amplification.
Summary of the Invention The present invention discloses an efficient high throughput method and device for isolating and quantifying mRNA directly from whole blood, with reproducible recovery, using combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.
One aspect of the invention includes a method of high throughput quantification of mRNA in whole blood, including the steps of: (a) collecting whole blood; (b) removing erythrocytes and blood components from the whole blood by filtration to yield leukocytes on a filter membrane; (c) subjecting the leukocytes to cell lysis to produce a lysate containing mRNA; (d) transferring the lysate to an oligo(dT)-immobilized plate to capture the mRNA; and (e) quantifying the mRNA. In one preferred embodiment of the method, an anticoagulant is administered to the whole blood prior to collection of leukocytes. Several filter membranes can be layered together to increase the yield of captured leukocytes. The leukocytes that are trapped on the filter membrane are lysed using a lysis buffer to release mRNA from the leukocytes. The transfer of lysate to the oligo(dT)-immobilized plate can be accomplished using centrifugation, vacuum aspiration, positive pressure, or washing with ethanol followed by vacuum aspiration. The mRNA is quantified by producing cDNA and amplifying the cDNA by PCR.
Another aspect of the invention includes a device for performing high throughput quantification of mRNA in whole blood, wherein the device includes: (a) a multi-well plate containing: a plurality of sample-delivery wells; a leukocyte-capturing filter underneath the wells; and an mRNA capture zone underneath the filter which contains immobilized oligo(dT); and (b) a vacuum box adapted to receive the filter plate to create a seal between
the plate and the box. In one preferred embodiment of the device, the leukocytes are captured on a plurality of filter membranes that are layered together. In another preferred embodiment of the device, the vacuum box is adapted to receive a source of vacuum. In another preferred embodiment of the device, a multi-well supporter is inserted between the vacuum box and the multi-well plates.
Another aspect of the invention includes a kit, which contains: the device for performing high throughput quantification of mRNA in whole blood, heparin, a hypotonic buffer, and a lysis buffer.
Another aspect of the invention includes a fully automated system for performing high throughput quantification of mRNA in whole blood, including: a robot to apply blood samples, hypotonic buffer, and lysis buffer to the device; an automated vacuum aspirator and centrifuge, and automated PCR machinery.
Brief Description of the Drawings FIG. 1 is an exploded drawing of the high throughput mRNA device.
FIG. 2 depicts the multi-well plate, including the leukocyte filter and oligo-(dT)- immobilized filter wells, of the high throughput mRNA device.
FIG. 3 is a graph showing the efficiency of leukocyte trapping of fresh and frozen blood samples on filter plates. FIG. 4 is a graph showing the effect of number of washes of blood on mRNA quantification.
FIG. 5 is a graph showing the effect of final treatments of filter plates before cell lysis on mRNA quantification.
FIG. 6 is a graph showing how lysis buffer inhibits RNase. FIG. 7 is a graph showing optimal concentrations of reverse transcriptase for mRNA quantification.
FIG. 8 is a graph showing optimal values of cDNA for PCR to capture mRNA. FIG. 9 is a graph showing the hybridization kinetics of the invention. FIG. 10 is a graph showing the linear relationship between whole blood volume used per well and mRNA quantification.
Detailed Description of the Preferred Embodiment
The present invention allows analysis of larger volumes of unprepared whole blood, provides an efficient means of analyzing mRNA that is derived exclusively from white blood cells; removes rRNA and tRNA, provides consistent mRNA recovery, and is easily adaptable to automation. The present invention provides a sensitive quantification system, including: absolute quantification using real time PCR, and excellent reproducibility with coefficients of variation ranging from 20-25%. Moreover, the present invention is applicable to various disease targets (Table I). Table I. Clinical targets
The invention is not limited to any particular mechanical structure. However, FIGs 1 and 2 show a preferred structure for implementing the high throughput mRNA quantification of the present invention. A vacuum box 10 forms the base of the structure. The vacuum box can be made of any material sufficiently strong to withstand vacuum aspiration; however, disposable plastic material is preferred. The vacuum box is adapted to receive a source of vacuum in order to perform vacuum aspiration 12. A filter plug 14 is located within the vacuum aspirator adapter of the vacuum box. The vacuum box 10 preferably has a ledge 16 to mate with a multi-well filter plate 40, or optionally, a multi- well supporter 20. The multi-well supporter 20 is optionally provided inside the upper part of the vacuum box so as to support the multi-well filterplate 40. A sealing gasket 30, preferably comprised of silicon-based rubber or other soft plastic, is located on top of the
multi-well supporter. Above the sealing gasket lies the multi-well filter plate 40, which contains multiple sample wells 46, multiple leukocyte-capturing filters 42 underneath the sample-delivery wells, and an mRNA capture zone 44 under the filter. Oligo(dT)- immobilized is contained in the wells of the mRNA capture zone. One preferred embodiment involves a simple, reproducible, and high throughput method of mRNA quantification from whole blood. The rapid protocol minimizes the secondary induction or degradation of mRNA after blood draw, and the use of 96-well filterplates and microplates allows the simultaneous manipulation of 96 samples. Minimal manipulation during the procedure provides for very small sample-to-sample variation, with coefficient of variation (CV) values of less than 30%, even when PCR is used as a means of quantification.
In one embodiment, the method involves preparation of the vacuum box. In one preferred embodiment, a blood encapsulator such as polyacrylate polymer matrix (Red Z, Safetec) is added to the vacuum box to solidify the blood. A multi-well supporter is then placed in the vacuum box. A sealing gasket made of silicon-based rubber or other soft plastics is then placed on top of the multi-well plate supporter. A filter plug (X-6953, 60 μ Filter Plug HDPE, Porex Products Groups) is placed in the vacuum aspirator adapter of the vacuum box. h this embodiment, the method involves the preparation of the filter plate. Either glassfiber membranes or leukocyte filter membranes can be used to capture leukocytes. In order to simplify the assay, multiple-well filterplates are constructed using glassfiber membranes or leukocyte filter membranes to enable the simultaneous processing of multiple blood specimens. Examples of filters for capturing leukocytes are disclosed in U.S. patent numbers 4,925,572 and 4,880,548, the disclosures of which are hereby incorporated by reference. Adsorption of leukocytes on fiber surfaces is generally accepted as the mechanism of leukocyte removal. Since the surface area of a given weight of fibers is inversely proportional to the diameter of the fibers, it is to be expected that finer fibers will have higher capacity and that the quantity as measured by weight of fibers necessary to achieve a desired efficiently will be less if the fibers used are smaller in diameter. A number of commonly used fibers, including polyesters, polyamides, and acrylics, lend themselves to radiation grafting, as they have adequate resistance to degradation by irradiation at the levels required for grafting and are of a structure with which available
monomers can react. PBT has been the principal resin used for the development of the products of this invention and is the resin used in the examples. It should be noted, however, that other resins may be found which can be fiberized and collected as mats or webs with fibers as small as 1.5 micrometers or less, and that such products, with their critical wetting surface tensions adjusted as necessary to the optimum range, may be well suited to the fabrication of equally efficient but still smaller leukocyte depletion devices. Similarly, glass fibers, appropriately treated, may be usable to make effective devices. Absorption of CD4 mRNA is up to four times as effective when using PBT-based filters as opposed to glass fiber-based filters. The filter plate is placed in the vacuum box. In another preferred embodiment, multiple filter membranes are layered together to increase the amount of leukocytes captured from whole blood. In one preferred embodiment, the filter plate is placed upon the plate supporter and the sealing gasket. In another preferred embodiment, the filter plate is sealed with a plastic adhesive tape (Bio-Rad 223-9444), and the tape is cut to allow access to a desired number of wells. In another preferred embodiment, each well to which a sample will be added is washed with a hypotonic buffer (200 μL 5mM Tris, pH 7.4).
The method preferably involves collecting blood, adding the blood to the multi-well filter plate, and removal of erythrocytes and other non-leukocyte components. In one preferred embodiment, whole blood can be drawn into blood collection tubes containing anticoagulants, which increase the efficiency of the leukocyte filtering. The anticoagulant, heparin, is particularly effective in increasing the efficiency of leukocyte filtering. In one preferred embodiment, the blood sample can be frozen, which removes some of the RNases that destroy mRNA. The wells can be washed with a hypotonic buffer. Once blood has been added to the desired number of wells on the filterplate, the blood is filtered through the filter membrane. Filtration can be affected through any technique known to those of skill in the art, such as centrifugation, vacuum aspiration, or positive pressure.
In one especially preferred embodiment, vacuum aspiration is commenced (with 6 cm Hg) after the blood samples have been added to the filterplate wells. Each well is washed several times with a hypotonic buffer (12x with 200 μL 5mM Tris, pH 7.4). In another preferred embodiment, each well containing a sample is washed with ethanol (lx with 200 μL 100% ethanol), which dries the filter membrane and significantly increases the
efficiency of leukocyte trapping during vacuum aspiration. In another preferred embodiment, the vacuum is then applied (20 cmHg for >2 min).
The method involves cell lysis and hybridization of mRNA to the oligo(dT)- immobilized within the mRNA capture zone. Lysis buffer is applied to the filterplate wells (40μL/well), and incubation is allowed to occur (room temperature for 20 min) to release mRNA from the trapped leukocytes. In one preferred embodiment, the multi-well filterplate is sealed in a plastic bag and centrifuged (IEC MultiRF, 2000 rpm, at 4 C, for 1 min). Lysis buffer is then added again (20 μL/well), followed by centrifugation (IEC MultiRF, 3000 rpm, at 4 C, for 5 min). The multi-well filterplate is then removed from the centrifuge and incubated (room temperature for 2hrs).
The method involves quantification of mRNA, which in a preferred embodiment entails cDNA synthesis from mRNA and amplification of cDNA using PCR. In one preferred embodiment, the multi-well filterplate is washed with lysis buffer (150 μL/well x 3 times, manual) and wash buffer (150 μL/well x 3 times, manual or BioTek #G4). A cDNA synthesis buffer is then added to the multi-well filterplate (40 μL/well, manual or I&J #6). Axymat (Amgen AM-96-PCR-RD) can be placed on the multi-well filterplate, which is then placed on a heat block (37 C, VWR) and incubated (>90 min). The multi- well filterplate can then be centrifuged (2000 rpm, at 4 C for 1 min). PCR primers are added to a 384 well PCR plate, and the cDNA is transferred from the multi-well filterplate to the 384 well PCR plate. The PCR plate is centrifuged (2000 rpm, at 4 C for 1 min), and real time PCR is commenced (TaqMan/SYBER).
Another preferred embodiment of the invention involves a device for high- throughput quantification of mRNA from whole blood. The device includes a multi-well filterplate containing: multiple sample-delivery wells, a leukocyte-capturing filter underneath the sample-delivery wells, and an mRNA capture zone under the filter, which contains oligo(dT)-immobilized in the wells of the mRNA capture zone. In order to increase the efficiency of leukocyte collection, several filtration membranes can be layered together. The multi-well plate is fitted upon a vacuum box, which is adapted to receive the plate and to create a seal between the multi-well plate and the vacuum box. In one preferred embodiment of the device, the vacuum box is adapted to receive a source of vacuum in order to perform vacuum aspiration. In another preferred embodiment, a multi- well supporter is placed in the vacuum box, below the multi-well filterplate. In another
preferred embodiment of the device, a sealing gasket, which can be made from soft plastic such as silicon-based rubber, is inserted between the multi-well supporter and the multi- well filterplate.
Another preferred embodiment involves a kit for high-throughput quantification of mRNA from whole blood. The kit includes: the device for high-throughput quantification of mRNA from whole blood; heparin-containing blood-collection tubes; a hypotonic buffer; and a lysis buffer.
Another preferred embodiment involves a fully automated system for performing high throughput quantification of mRNA in whole blood, including: robots to apply blood samples, hypotonic buffer, and lysis buffer to the device; an automated vacuum aspirator and centrifuge, and automated PCR machinery.
Example Various protocols of the method of the present invention were tested and used to quantify β-actin mRNA and CD4 mRNA from whole blood.
Three anticoagulants were tested: ACD, EDTA, and heparin, with heparin resulting in the highest percent of leukocyte retention. While Leukosorb membranes have been used for ACD blood in transfusion, approximately 15-40% of leukocytes passed through even when four layers of membranes were simultaneously used. EDTA blood was tested; the capacity and leukocyte retention was found to be similar to those for ACD. Most notably, however, was that 100% of the leukocytes in heparin blood were trapped on the Leukosorb membranes. The capture of 100% of leukocytes from heparin blood shows the reliability of quantification of mRNA using the present invention. These data indicate that the use of heparin blood is most suitable for the precise quantification of mRNA, whereas ACD blood is useful for applications requiring larger volumes of blood and less quantitative results.
The results of using of frozen versus fresh blood samples was compared. As indicated in FIG 3, more CD4 mRNA was recovered from leaked cells of fresh blood than from leaked cells of frozen samples.
The effectiveness of whole blood retention of glassfiber filters, as compared to retention values of PBT-based filter membranes, was also examined. As shown in Table II, glassfiber membranes accepted only 40 μL of whole blood, even when membranes were washed with hypotonic buffer (50 mM Tris, pH 7.4) to burst erythrocytes. Leukosorb
filters, however, accepted significantly larger amounts of whole blood than the glassfiber filters, as indicated in Table II.
Table II. Amplification of β-actin mRNA From Whole Blood
A: ACS, E: EDTA, H: heparin
(A, H) represents anticoagulants used in the experiments.
(CT: Threshold Cycle
CV: Coefficient of variation
10 Various numbers of washes with hypotonic buffer were applied to remove erythrocytes and other blood components. As indicated in FIG 4, washing the samples with hypotonic buffer at least three times more than doubled the amount of CD4 mRNA that was captured as compared to no washing. FIG 4 also shows that washing the blood twelve times with hypotonic buffer resulted in the capture of the most mRNA.
15 Additionally, various methods of vacuuming, centrifuging, and washing with ethanol followed by vacuuming blood samples to collect leukocytes were compared with respect to final CD4 mRNA quantification. FIG 5 indicates that while vacuum aspiration resulted in better CD4 mRNA quantification than centrifugation, washing blood samples with ethanol prior to vacuum aspiration yields the most mRNA.
20 Once the leukocytes were trapped on the glassfiber or Leukosorb membranes, various numbers of washes with hypotonic buffer were applied to remove erythrocytes and other blood components. To release mRNA from the trapped leukocytes, lysis buffer (KNAture) was applied to the filterplates (40 μL/Well), and the plates were incubated at room temperature for 20 minutes. In a preferred embodiment, amplification primers are
25 included in the lysis buffer. FIG 6 indicates that lysis buffer plays an important role in RNase inhibition; eosinophils are filled with RNases, which are inactivated by the lysis
buffer. The multi-well filterplate was then sealed in a plastic bag and centrifuged (IEC MultiRF, 2000 rpm, at 4 C, for 1 min). Lysis buffer was then added again (20 μL/well), followed by centrifugation (IEC MultiRF, 3000 rpm, at 4 C, for 5 min). The multi-well filterplate was then removed from the centrifuge and incubated at room temperature for two hours to allow hybridization of poly(A)+ RNA tails with the immobilized oligo(dT). The multi-well filterplates were then washed three times with 150 μL Lysis Buffer to remove remaining ribonucleases, followed by three washes with 150 μL Wash Buffer (BioTek #G4) to remove the Lysis Buffer, which contained some inhibitors of cDNA synthesis.
Upon the final wash, the Wash Buffer was completely removed from the multi-well filterplates, and cDNA was synthesized in each well by adding 40 μL of premixed cDNA buffer. The cDNA buffer consists of: 5x First Strand Buffer (Promega M531A, 10 mM dNTP (Promega stock, 20x)), Primer (5 μM, #24), RNasin (Promega N211A, 40 U/μL), M-MLV reverse transcriptase (Promega M170A, 200 U/μL), and DEPC water. FIG 7 indicates that the optimal concentration of MMLV for mRNA quantification is 0.25 units/well.
Axymat (Amgen AM-96-PCR-RD) was placed on the multi-well filterplate, which was then placed on a heat block (37 C, VWR) and incubated (>90 min). The multi-well filterplate was then centrifuged (2000 rpm, at 4 C for 1 min). PCR primers were added to a 384-well PCR plate, and the cDNA was transferred from the multi-well filterplate to the 384-well PCR plate. FIG 8 indicates that the optimal value of cDNA for PCR is approximately 2 μL/well. The PCR plate was centrifuged (2000 rpm, at 4 C for 1 min), and real time PCR was commenced (TaqMan/SYBER). The method of the current invention has high mRNA specificity; amplification of CD4 mRNA with TaqMan qPCR resulted in undetectable DNA contamination (<10 copies/well). As indicated in FIG 9, the present invention results in low coefficients of variation for mRNA quantification. Hybridization for two hours resulted in a coefficient of variation of less than 13%, as compared to traditional coefficients of variation of approximately 300% for mRNA quantification. Moreover, as indicated in FIG 10, the linear results show that the amount of mRNA that is captured is directly proportional to the volume of whole blood used per well, making the present invention a reliable and reproducible method of quantifying mRNA.
Claims
WHAT IS CLAIMED IS:
1. A method of high throughput quantification of a specific mRNA in whole blood, comprising the steps of:
(a) collecting whole blood;
(b) removing erythrocytes and blood components other than leukocytes from the whole blood by filtration to yield leukocytes on a filter membrane;
(c) lysing the leukocytes on a filter membrane to produce a lysate comprising mRNA;
(d) transferring the lysate to an oligo(dT)-immobilized plate to capture the mRNA; and
(e) quantifying the specific mRNA
2. The method of Claim 1, wherein an anticoagulant is administered to the whole blood prior to collection of leukocytes.
3. The method of Claim 1, wherein heparin is administered to the whole blood prior to collection of leukocytes.
4. The method of Claim 1 , wherein the whole blood is frozen prior to filtration.
5. The method of Claim 1, wherein the filter membrane is attached to a multi- well filter plate.
6. The method of Claim 1, wherein the filter membrane is a PBT fibrous membrane.
7. The method of Claim 5, wherein the leukocytes are captured on a plurality of filter membranes layered together. 8. The method of Claim 1, additionally comprising washing the leukocytes on the filter membrane with hypotonic buffer to further remove erythrocytes and other blood components.
9. The method of Claim 8, additionally comprising drying the filter membrane.
10. The method of Claim 9, wherein the filter membrane is washed with ethanol and subjected to vacuum aspiration until the filter membrane is dry.
11. The method of Claim 1, wherein the immobilized plate comprises a multi- well oligo(dT)-immobilized plate.
12. The method of Claim 1, wherein the transfer of lysate to the oligo(dT)- immobilized plate comprises centrifugation.
13. The method of Claim 1, wherein the transfer of lysate to the oligo(dT)- immobilized plate comprises vacuum aspiration. 14. The method of Claim 1, wherein the transfer of lysate to the oligo(dT)- immobilized plate comprises applying positive pressure.
15. The method of Claim 1, wherein the quantification of mRNA comprises cDNA synthesis of the specific mRNA and amplification of resulting cDNA.
16. The method of Claim 1 , wherein the mRNA quantified is a-actin mRNA. 17. The method of Claim 1 , wherein the mRNA quantified is CD4 mRNA.
18. The method of Claim 1 , wherein the mRNA of a translocation gene involved in leukemia is quantified.
19. The method of Claim 1, wherein the mRNA of cancer-specific genes from micrometastatic cancer is quantified. 20. The method of Claim 1, wherein virus-derived mRNA from infected white blood cells is quantified.
21. The method of Claim 20, wherein the quantified virus-derived mRNA is HIV
22. The method of Claim 21, wherein the quantification of HIV mRNA is used to diagnose HIV.
23. The method of Claim 20, wherein the quantified virus-derived mRNA is CMV.
24. The method of Claim 23 , wherein the quantification of virus-derived mRNA is used to diagnose CMV. 25. The method of Claim 20, wherein the quantification of virus-derived mRNA is used to monitor blood banks for the presence of viral diseases.
26. The method of Claim 20, wherein the quantification of virus-derived mRNA is used to study anti- viral drug sensitivity.
27. The method of Claim 1, wherein the mRNA of apoptosis genes involved in leukemia is quantified.
28. The method of Claim 1 , wherein the mRNA of cytokines is quantified.
29. The method of Claim 1, wherein the quantification of mRNA is used to test side effects of anti-cancer drugs on white blood cells.
30. The method of Claim 1, wherein the mRNA of DNA-repair genes is quantified. 31. The method of Claim 30, wherein the quantification of mRNA of DNA- repair genes is used to test the sensitivity of DNA-repair genes to radiation.
32. The method of Claim 1, wherein the mRNA of allergen response genes is quantified.
33. The method of Claim 32, wherein the quantification of mRNA of allergen response genes is used to test allergen stimulation.
34. The method of Claim 1, wherein the mRNA of donor cell-mediated cytokines is quantified.
35. The method of Claim 34, wherein the quantification of mRNA of donor cell- mediated cytokines is used to test transplant rejection. 36. A high throughput mRNA quantification device, comprising:
(a) a multi-well plate, said multi-well plate comprising: i) a plurality of sample-delivery wells;
ii) a leukocyte-capturing filter underneath said wells; iii) an mRNA capture zone underneath said filter, said mRNA capture zone having oligo(dT)-immobilized thereon; and (b) a vacuum box adapted to receive said plate to create a seal between said plate and said box.
37. The device of Claim 36, said vacuum box being adapted to receive a source of vacuum. 38. The device of Claim 36, said vacuum box being made of plastic.
39. The device of Claim 36, wherein said seal comprises a plastic-based gasket placed below the multi-well plate.
40. The device of Claim 36, wherein a multi-well supporter is inserted between the vacuum box and the multi-well plate. 41. The device of Claim 36, wherein the leukocytes are captured on a plurality of filter membranes layered together.
42. A high throughput mRNA quantification kit, comprising:
(a) the high throughput mRNA quantification device of Claim 36; (b) a hypotonic buffer;
(c) ethanol; and
(d) a lysis buffer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37547202P | 2002-04-24 | 2002-04-24 | |
US375472P | 2002-04-24 | ||
PCT/US2003/012895 WO2003091407A2 (en) | 2002-04-24 | 2003-04-24 | Device and method for high-throughput quantification of mrna from whole blood |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1504121A2 EP1504121A2 (en) | 2005-02-09 |
EP1504121A4 true EP1504121A4 (en) | 2005-06-29 |
Family
ID=29270646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03724238A Withdrawn EP1504121A4 (en) | 2002-04-24 | 2003-04-24 | Device and method for high-throughput quantification of mrna from whole blood |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1504121A4 (en) |
JP (1) | JP2005525114A (en) |
CN (1) | CN1650027B (en) |
WO (1) | WO2003091407A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208501A1 (en) * | 2004-03-16 | 2005-09-22 | Ambion, Inc. | Process and reagents for extraction of RNA from fractionated blood leukocytes |
EP1888089B9 (en) * | 2005-04-28 | 2012-08-08 | Hitachi Chemical Research Center, Inc. | Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements |
CA2652454C (en) * | 2006-05-24 | 2013-04-30 | Gen-Probe Incorporated | Compositions, methods and kits for determining the presence of mycobacterium tuberculosis complex organisms in a test sample |
ES2717940T3 (en) * | 2007-07-23 | 2019-06-26 | Alere Tech Gmbh | essays |
KR101511889B1 (en) * | 2011-02-17 | 2015-04-13 | 네스텍 소시에테아노님 | Apparatus and method for isolating leukocytes and tumor cells by filtration |
CN106190817B (en) * | 2016-07-19 | 2019-01-08 | 温州市高亿诺生物科技有限公司 | Nucleic acid cleavage liquid separating method and device based on porous plate |
CN106119382B (en) * | 2016-07-19 | 2018-08-28 | 湖州高亿诺生物科技有限公司 | Automate microbial molecules detection method and its application |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02295485A (en) * | 1989-05-09 | 1990-12-06 | Nissho Corp | Extraction of dna |
WO1994008239A1 (en) * | 1992-10-02 | 1994-04-14 | The Minister Of Agriculture, Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Detection of antigens and nucleic acids |
WO1999032654A1 (en) * | 1997-12-22 | 1999-07-01 | Hitachi Chemical Co., Ltd. | Direct rt-pcr on oligonucleotide-immobilized pcr microplates |
US5976797A (en) * | 1996-12-20 | 1999-11-02 | Hitachi Chemical Co., Ltd. | Method for quantifying total mRNA with poly(A)-complementary oligonucleotide-immobilized microtiter plate |
WO2000021973A1 (en) * | 1998-10-09 | 2000-04-20 | Whatman Bioscience Limited | Isolation method for nucleic acid and apparatus |
US6136555A (en) * | 1993-07-09 | 2000-10-24 | Cambridge Molecular Technologies Limited | Purification method and apparatus |
WO2000077253A1 (en) * | 1999-06-16 | 2000-12-21 | Hitachi, Ltd. | Apparatus and method for gene examination |
WO2002014560A1 (en) * | 2000-08-16 | 2002-02-21 | Whatman, Inc. | Transfusion medicine leukodepletion filter devices as a source of genetic material for genotyping studies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US625229A (en) * | 1899-05-16 | Machine for forging horseshoe-nails or other articles | ||
NO180658C (en) * | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Method and Device for Detecting Specific Target Cells in Specialized or Mixed Cell Populations and Solutions Containing Mixed Cell Populations |
-
2003
- 2003-04-24 EP EP03724238A patent/EP1504121A4/en not_active Withdrawn
- 2003-04-24 JP JP2003587943A patent/JP2005525114A/en active Pending
- 2003-04-24 WO PCT/US2003/012895 patent/WO2003091407A2/en active Application Filing
- 2003-04-24 CN CN03809293.XA patent/CN1650027B/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02295485A (en) * | 1989-05-09 | 1990-12-06 | Nissho Corp | Extraction of dna |
WO1994008239A1 (en) * | 1992-10-02 | 1994-04-14 | The Minister Of Agriculture, Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Detection of antigens and nucleic acids |
US6136555A (en) * | 1993-07-09 | 2000-10-24 | Cambridge Molecular Technologies Limited | Purification method and apparatus |
US5976797A (en) * | 1996-12-20 | 1999-11-02 | Hitachi Chemical Co., Ltd. | Method for quantifying total mRNA with poly(A)-complementary oligonucleotide-immobilized microtiter plate |
WO1999032654A1 (en) * | 1997-12-22 | 1999-07-01 | Hitachi Chemical Co., Ltd. | Direct rt-pcr on oligonucleotide-immobilized pcr microplates |
WO2000021973A1 (en) * | 1998-10-09 | 2000-04-20 | Whatman Bioscience Limited | Isolation method for nucleic acid and apparatus |
WO2000077253A1 (en) * | 1999-06-16 | 2000-12-21 | Hitachi, Ltd. | Apparatus and method for gene examination |
WO2002014560A1 (en) * | 2000-08-16 | 2002-02-21 | Whatman, Inc. | Transfusion medicine leukodepletion filter devices as a source of genetic material for genotyping studies |
Non-Patent Citations (3)
Title |
---|
COLLETT M S; ANDERSON D K; RETZEL E: "COMPARISONS OF THE PESTIVIRUS BOVINE VIRAL DIARRHEA VIRUS WITH MEMBERS OF THE FLAVIVIRIDAE", JOURNAL OF GENERAL VIROLOGY, vol. 69, no. 10, 1988, pages 2637 - 2643 * |
PATENT ABSTRACTS OF JAPAN vol. 015, no. 068 (C - 0807) 18 February 1991 (1991-02-18) * |
QIAGEN: "RNeasy MinElute Cleanup Handbook", QIAGEN, April 2003 (2003-04-01), pages 1 - 30 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003091407A3 (en) | 2004-12-16 |
EP1504121A2 (en) | 2005-02-09 |
CN1650027B (en) | 2010-04-21 |
JP2005525114A (en) | 2005-08-25 |
CN1650027A (en) | 2005-08-03 |
WO2003091407A2 (en) | 2003-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1682678B1 (en) | Device and method for high-throughput quantification of mrna from whole blood | |
RU2556130C2 (en) | Selective cell lysis | |
JP4801630B2 (en) | Method and unit for preparing samples for liquid microbial analysis | |
EP1776471B1 (en) | Method of measuring cancer susceptibility | |
JP2011200236A (en) | Process and reagent for extraction of rna from fractionated blood leukocyte | |
EP2315852B1 (en) | Method for determining the origin of a sample | |
WO2017040515A1 (en) | Molecular methods for assessing post kidney transplant complications | |
EP3052661A2 (en) | Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens | |
JPH11235171A (en) | Sample processing using ion exchange resin | |
Nestorova et al. | Lab-on-a-chip mRNA purification and reverse transcription via a solid-phase gene extraction technique | |
WO2003091407A2 (en) | Device and method for high-throughput quantification of mrna from whole blood | |
US20160186167A1 (en) | Method and Device for Processing a Sample of Biological Material Containing Target Cells and Companion Cells in Order to Extract Nucleic Acids of the Target Cells | |
US20130052647A1 (en) | Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery | |
EP3535408A1 (en) | Method and apparatus for selective removal of cells from a cell suspension by mechanical lysis | |
WO2017080714A1 (en) | Method of processing nucleic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041119 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050517 |
|
17Q | First examination report despatched |
Effective date: 20060719 |
|
17Q | First examination report despatched |
Effective date: 20060719 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20090831 |